CAAS Capital Management’s Maravai LifeSciences MRVI Stock Holding History

CAAS Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-34,000	Closed	-$487K	–	839
2022 Q4	$487K	Buy	+34,000	New	+$535K	0.03%	481
2021 Q4	–	Sell	-518,745	Closed	-$25.5M	–	980
2021 Q3	$25.5M	Buy	+518,745	New	+$25.3M	0.51%	40
2021 Q1	–	Sell	-700,000	Closed	-$19.6M	–	1321
2020 Q4	$19.6M	Buy	+700,000	New	+$19.5M	0.19%	117

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

CAAS Capital Management's MRVI Position: Q1 2023 in Review

CAAS Capital Management sold out of Maravai LifeSciences (MRVI) in Q1 2023, closing a stake of 34,000 shares — an estimated $487K sold.

CAAS Capital Management first reported a position in MRVI in Q4 2020 and held it in 3 quarters. The position peaked at $25.5M in Q3 2021. 219 funds tracked by Wall St. Rank hold MRVI as of Q1 2023.

CAAS Capital Management reported no remaining Maravai LifeSciences position as of Q1 2023 after selling out during the quarter.
CAAS Capital Management sold 34,000 Maravai LifeSciences shares in Q1 2023, an estimated $487K.
CAAS Capital Management first reported a position in Maravai LifeSciences in Q4 2020 and held it in 3 quarters.
CAAS Capital Management's Maravai LifeSciences position peaked at $25.5M in Q3 2021.
219 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.